Elsevier

The Lancet Neurology

Volume 3, Issue 7, July 2004, Pages 431-434
The Lancet Neurology

Rapid Review
Metals in our minds: therapeutic implications for neurodegenerative disorders

https://doi.org/10.1016/S1474-4422(04)00809-9Get rights and content

Section snippets

Metals, amyloid-β (Aβ) peptide, and AD

The basis for MPAC studies in AD is evidence for Aβ precipitation and toxicity owing to abnormal interactions with copper, iron, and zinc.3, 12, 13, 14, 15, 16 Amyloid precursor protein (APP) has copper binding domains that allow it to function as a copper chaperone in the brain.15 There is evidence that copper and iron interact with Aβ to facilitate enzymatic production of hydrogen peroxide, which auto-oxidises Aβ and creates protease resistant soluble and crosslinked Aβ.14, 15, 16 There is

Clioquinol as a prototype MPAC: animal studies

Clioquinol was identified as a prototype MPAC after examining known molecules.2, 22 In post-mortem AD tissue, addition of clioquinol doubled the amount of soluble Aβ released; most Aβ was made soluble with repeated extraction.22 In a 12 week, blind, controlled study of 12-month-old transgenic mice (APP2576 Tg mice, which have AD-type neuropathology), it was determined that clioquinol at a dose of 20 mg/kg/day (but not at a dose of 2 mg/kg/day) significantly decreased sedimentable Aβ with two

Studies of clioquinol in patients with AD

In an initial uncontrolled study, 20 patients with mild to moderate AD received 20 mg or 80 mg of clioquinol daily for 21 days.23 Some cognitive improvements were noted with the higher dose and none had treatment related adverse events. A subsequent 36 week, phase II, placebo-controlled trial in 36 patients with mild to moderate AD was done in patients on stable cholinesterase-inhibitor therapy.24 Clioquinol dose was 125 mg twice daily (weeks 0–12), 250 mg twice daily (weeks 13–24), and 375 mg

Safety issues with clioquinol

Clioquinol was used extensively in the mid 1900s as an antibiotic, but was banned in Japan in 1970 after it was associated with 10 000 cases of SMON.26, 27 This disorder is characterised by subacute onset of visual impairment and sensory and motor disorders in the lower half of the body. Epidemiological studies have linked SMON to clioquinol25 and studies in dogs have replicated clinical features of SMON.28 Mitochondrial toxicity caused by clioquinol-zinc chelate has been proposed as a

MPAC in other neurodegenerative diseases

Studies have described abnormal protein-metal interactions in neurodegenerative diseases—eg, PD, Creutzfeldt-Jakob disease, familial amyotrophic lateral sclerosis, and Freidrich's ataxia (table).1, 5, 6, 7, 8, 9, 10, 11, 32, 33, 34, 35 In many of these disorders it is still unclear if metal dyshomeostasis is a primary causal factor, a secondary contributor, or simply a consequence of the neurodegeneration.

Post mortem and MRI studies in PD have found high concentrations of iron in the substantia

Conclusion

The recent studies of clioquinol in AD and PD provide a new approach to treatment as well as new insights into these disorders. However, whether metal dyshomoeostasis is a primary causal factor of AD or PD, a secondary contributor, or simply a consequence is unknown. Effects of dietary metal supplements on the brain needs further study. Although clioquinol is not the optimal MPAC for therapy, the potential for development of MPAC therapy in neurodegenerative diseases with aberrant metal-protein

Search strategy and selection criteria

References for this review were identified by searches, from Jan 2003-March 2004, of MEDLINE with the terms “Alzheimer's”, “Parkinson's”, or “neurodegeneration” combined with either “metals” or “clioquinol”. References were also identified from relevant articles and through searches of the authors’ files. Abstracts and reports from meetings were included only when they related directly to previously published work. Only papers published in English were reviewed.

First page preview

First page preview
Click to open first page preview

References (36)

  • KJ Barnham et al.

    Metalprotein attenuating compounds (MPACs) for the treatment of Alzheimer's disease

    Drug Design Reviews Online

    (2004)
  • A Finefrock et al.

    Current status of metals as therapeutic targets in Alzheimer's disease

    J Am Geriatr Soc

    (2003)
  • S Pitchumoni et al.

    Current status of antioxidant therapy for Alzheimer's disease

    J Am Geriatr Soc

    (1998)
  • CW Levenson

    Iron and Parkinson's disease: Chelators to the rescue?

    Nutr Rev

    (2003)
  • DR Brown et al.

    Normal prion protein has an activity like that of superoxide dismutase

    Biochem J

    (2000)
  • AG Estevez et al.

    Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase

    Science

    (1999)
  • WG Campbell et al.

    Iron pigment in the brain of a man with tardive dyskinesia

    Am J Psychiatry

    (1985)
  • B Drayer et al.

    Reduced signal intensity on MR images of thalamus and putamen in multiple sclerosis: increased iron content?

    AJR Am J Roentgenol

    (1987)
  • Cited by (161)

    • Design, synthesis and evaluation of novel scutellarin and scutellarein-N,N-bis-substituted carbamate-L-amino acid derivatives as potential multifunctional therapeutics for Alzheimer's disease

      2022, Bioorganic Chemistry
      Citation Excerpt :

      Another important contributor to the progression of AD is abnormally high levels of metal ions such as Cu2+, Fe2+, Al3+and Zn2+. The presence of these metal ions in the brain might contribute to overproduction of reactive oxygen species (ROS), resulting in oxidative stress that further promotes Aβ toxicity by production of free radicals and increasing the generation of Aβ peptides [17,18]. Thus, biometal chelators could be a promising therapy to reduce Aβ aggregates for treatment of AD.

    • Metal Toxicity Links to Alzheimer's Disease and Neuroinflammation

      2019, Journal of Molecular Biology
      Citation Excerpt :

      Therefore, zinc is intimately linked to the balance of excitation and inhibition signaling in the brain and is essential for memory function and behavior [145]. Zinc homeostasis is impacted in a wide-range of neurological diseases [146,147]. Although zinc lacks redox activity, it has been demonstrated that excess zinc in the extracellular fluid promotes neurotoxicity and affects protein aggregation [148–150].

    View all citing articles on Scopus
    View full text